[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 210", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 758 8672", "website": "https://www.sqzbiotech.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 53, "companyOfficers": [{"maxAge": 1, "name": "Dr. Robert S. Langer Jr., Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1949, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  First", "age": 59, "title": "Chief People Officer", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ipsita  Roymoulik Ph.D.", "title": "Senior Vice President of CMC & QUALITY", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1704067200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0331, "open": 0.0336, "dayLow": 0.0331, "dayHigh": 0.03665, "regularMarketPreviousClose": 0.0331, "regularMarketOpen": 0.0336, "regularMarketDayLow": 0.0331, "regularMarketDayHigh": 0.03665, "beta": 1.377, "forwardPE": -0.0015384615, "volume": 1808200, "regularMarketVolume": 1808200, "averageVolume": 150921, "averageVolume10days": 105490, "averageDailyVolume10Day": 105490, "marketCap": 1032188, "fiftyTwoWeekLow": 0.01, "fiftyTwoWeekHigh": 0.9, "priceToSalesTrailing12Months": 0.085157, "fiftyDayAverage": 0.0251, "twoHundredDayAverage": 0.20872, "currency": "USD", "enterpriseValue": 12311189, "floatShares": 24250257, "sharesOutstanding": 29491100, "sharesShort": 811150, "sharesShortPriorMonth": 743030, "sharesShortPreviousMonthDate": 1684108800, "dateShortInterest": 1686787200, "sharesPercentSharesOut": 0.0275, "heldPercentInsiders": 0.02099, "heldPercentInstitutions": 0.25528, "shortRatio": 27.26, "shortPercentOfFloat": 0.030299999, "impliedSharesOutstanding": 29491100, "bookValue": 0.064, "priceToBook": 0.546875, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -71643000, "trailingEps": -2.43, "forwardEps": -22.75, "enterpriseToRevenue": 1.016, "enterpriseToEbitda": -0.208, "52WeekChange": -0.96024096, "SandP52WeekChange": 0.21733451, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "SQZB", "underlyingSymbol": "SQZB", "shortName": "SQZ Biotechnologies Company", "longName": "SQZ Biotechnologies Company", "firstTradeDateEpochUtc": 1604064600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "664eacc6-ba56-3fc6-8c6c-d9dbde46168f", "messageBoardId": "finmb_261457741", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.035, "targetHighPrice": 22.0, "targetLowPrice": 22.0, "targetMeanPrice": 22.0, "targetMedianPrice": 22.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 10193000, "totalCashPerShare": 0.346, "ebitda": -59061000, "totalDebt": 21472000, "quickRatio": 1.154, "currentRatio": 1.369, "totalRevenue": 12121000, "debtToEquity": 1141.52, "revenuePerShare": 0.411, "returnOnAssets": -0.41138, "returnOnEquity": -2.03372, "freeCashflow": -29514376, "operatingCashflow": -74334000, "operatingMargins": -5.01337, "financialCurrency": "USD", "trailingPegRatio": null}]